Genomics, proteomics, and other branches of molecular bioscience offer the possibility of greater precision in medical care by tailoring therapies to patients' genetic or molecular profiles. But some clinical tests based on "omics" research, including tests developed by researchers at Duke University to select chemotherapy for cancer patients, have proved invalid. Evolution of Translational Omics: Lessons Learned and the Path Forward, a new report from the Institute of Medicine, recommends steps to help avoid future problems associated with moving omics-based discoveries from the lab to clinical settings.
Advance copies will be available to reporters only beginning at 10 a.m. EDT Thursday, March 22. The report is embargoed and not for public release before noon EDT Friday, March 23. Members of the committee that wrote the report will discuss their recommendations during a telephone news conference beginning at noon EDT on March 23. To obtain an embargoed copy and the conference dial-in number or arrange an interview with a committee member, reporters should contact the National Academies’ Office of News and Public Information; tel. 202-334-2138 or e-mail firstname.lastname@example.org.